Investor Overview

Corporate Profile

Verastem Oncology (Nasdaq: VSTM) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on RAS/MAPK-driven cancers, specifically novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition.

Investor Contact
Julissa Viana

Investor Relations
investors@verastem.com

Ryan Porter

Argot Partners
+1 212-600-1902
ryan.porter@argotpartners.com